Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Lasofoxifene in combination with abemaciclib
DRUG: Fulvestrant in combination with abemaciclib

Sponsor

LeonaBio